View details of this raise on Seedstage

Rochester, NY

Developing next-generation cancer therapies targeting the KAHF receptor.

• Novel Target: A novel target in PDAC with limited prior characterization and promising preclinical validation.
• Dual Strategy: Dual therapeutic strategy blocks metastasis early and kills tumors in late-stage disease.
• Platform Approach: Platform approach expandable to multiple solid tumors expressing the same receptor.
• Lead Antibody Expansion: Lead antibody can be expanded into ADC or Degrader Antibody conjugates (DACs).
• Experienced Leadership: Founded by a PhD cancer scientist with deep expertise in cancer therapeutic development platforms.

KAHF Biotech is developing innovative cancer therapies targeting the KAHF receptor to halt tumor progression and metastasis. The company is focused on creating an optimized Anti-KAHF Monoclonal Antibody as a new biological drug, initially targeting Pancreatic Ductal Adenocarcinoma (PDAC) and expanding to other solid tumors. The KAHF receptor is highly expressed in PDAC cells, and the Anti-KAHF mAb has shown potential in increasing cell death and reducing invasion in preclinical studies.

The seed round aims to generate a patent-protected Anti-KAHF mAb ready for IND-enabling studies. KAHF Biotech’s platform approach allows for the expansion of the lead antibody into multiple therapeutic assets, including Antibody Drug Conjugates and Degrader Antibody Conjugates. The company is a spinout from research conducted at the Wilmot Cancer Center, with a mission to pioneer next-generation cancer therapies.

Company Info

KAHF Biotech develops targeted cancer therapies focusing on the KAHF receptor to combat tumor progression and metastasis.

KAHF Biotech is a biotechnology company focused on developing innovative cancer therapies targeting the KAHF receptor. The company aims to halt tumor progression and metastasis, particularly in pancreatic ductal adenocarcinoma (PDAC), by utilizing a novel monoclonal antibody approach. Their lead product, Anti-KAHF mAb, is designed to inhibit key processes such as epithelial-mesenchymal transition, survival, invasion, and drug resistance in cancer cells.

Founded by a PhD cancer scientist, KAHF Biotech operates from Rochester, New York, and is a spinout from research conducted at the Wilmot Cancer Center. The company employs a dual therapeutic strategy that not only blocks metastasis early but also targets tumors in late-stage disease. Their platform approach is adaptable to multiple solid tumors, with potential expansions into antibody-drug conjugates and other therapeutic modalities.